Loading...
Skip to main content

Articles

2020

Interview with Prof. Dr Gerald Prager
21 September 2020
The role of trifluridine/tipiracil in mCRC and mGC Video
Read more
EXPERT OPINION – The role of trifluridine/tipiracil in...
20 July 2020
Prof. Dr Gerald PragerMedical University of Viennaand Comprehensive Cancer Center Vienna Vienna, Austria EXPERT OPINION
Read more
Press Release Servier – Symphogen
28 May 2020
Servier a annoncé le 3 avril dernier la signature d’un accord définitif avec les dirigeants de Symphogen pour acquérir 100 % du capital de la société.
Read more

2019

(In process in Switzerland): ESMO Update for 3rd...
22 November 2019
The ESMO Guidelines Committee has published an update on the management of advanced/metastatic Gastric cancer in second–and further-line treatment - indicating that LONSURF is now recommended in third-line for patients...
Read more
Scan Daily Oncology 06/09/2019
13 September 2019
LONSURF® (trifluridine/tipiracil) Receives Marketing Authorization in Europe for Patients With Previously Treated Metastatic Gastric Cancer
Read more
PRESS RELEASE ONIVYDE SCLC World Lung Congress
13 September 2019
Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference...
Read more
PRESS RELEASE LONSURF EC approval mGC indication
9 September 2019
LONSURF® (trifluridine/tipiracil) Receives Marketing Authorization in Europe for Patients with Previously Treated Metastatic Gastric Cancer.
Read more
PRESS RELEASE LONSURF CHMP opinion
15 August 2019
LONSURF® (trifluridine/tipiracil) Receives Positive Opinion from CHMP in the EU for Patients with Previously Treated Metastatic Gastric Cancer
Read more
PRESS RELEASE ONIVYDE
12 July 2019
Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer.
Read more
PRESS RELEASE ASCO 2019
17 June 2019
A press release from Servier international about ASCO 2019 held in Chicago.
Read more
Swiss Statement mCRC
19 March 2019
The latest Healthbook Special TAS-102 + 4 KOL Statements Report is now available, order it now via materials.   190123 HB_Special TAS-102 + 4 KOL Statements Report_FR_1 190123 HB_Special TAS-102...
Read more
FDA mGC registration
18 March 2019
Press release announcing that the FDA Approves Taiho Oncology's LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.  
Read more

2018

TAGS (TAS-102 Gastric Study) press release
31 October 2018
Press release announcing that the TAGS study has met primary and secondary endpoints.
Read more
Servier in Oncology – Committed to therapeutic progress
3 September 2018
Read more
Dr. Med. Mac Ramos – mCRC – Beyond...
19 March 2018
An article by Dr. Med. Mac Ramos dealing with the incidence of CRC/mCRC and therapy options available after 2 progressions.
Read more
Dr. Med. T. Winder, PhD – Adjuvant treatment...
19 February 2018
Evaluation by Priv.-Doz. Dr. Thomas Winder, PhD of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA), an academic collaboration from six randomized phase III clinical trials from 12 countries including...
Read more
Trifluridine/Tipiracil – Mode of action
19 January 2018
A sequence nicely illustrating the mode of action of each component from Trifluridine/Tipiracil and then comparing it with 5-FU mode of action.
Read more

2017

RECOURSE: TAS-102 Phase III Trial
19 December 2017
A summary of the RECOURSE clinical trial. RECOURSE is the international, randomised, double-blind, placebo-controlled phase III clinical trial assessing the efficacy and safety of the combination trifluridine/tipiracil for refractory metastatic...
Read more
TAS-102: Phase II Trial
19 November 2017
A summary of the Japanese phase II Trial conducted on 169 patients assessing the efficacy and the safety of TAS-102 in monotherapy for refractory metastatic colorectal cancer patients.
Read more
mCRC therapy lines overview
30 October 2017
An overview of mCRC patients eligible by lines of therapies and the most frequently treatment used for each line, thus showing the need for new therapy options in later lines.
Read more